Clinical trials are excellent at measuring things. They measure lung capacity, walking distance, questionnaire scores. What they rarely measure is something much simpler: what did the patient actually feel?

A new study, published in BMC Complementary Medicine and Therapies on October 15, 2026, asked that question directly. Researchers from Wonkwang University and Kyung Hee University in South Korea sat down with eleven patients living with chronic obstructive pulmonary disease (COPD) — all of whom had tried East Asian traditional medicine — and conducted in-depth interviews until no new themes emerged. The result is not a verdict on whether these therapies "work." It is something rarer and, in a way, more useful: a careful account of how patients experience them, and a quiet critique of how research measures them.

The Gap This Study Fills

COPD narrows the airways, traps air in the lungs, and steadily erodes a person's ability to breathe freely. Standard care — bronchodilators, inhaled corticosteroids, pulmonary rehabilitation, smoking cessation — slows the decline, but many patients continue to live with persistent breathlessness, chronic sputum, and fatigue. That residual burden is precisely what pushes a substantial number of patients toward traditional medicine: herbal formulas, manual therapy (chuna in Korean, tuina in Chinese), and acupuncture.

Trials have tested these modalities as adjuncts to standard care. But remarkably little was known about how patients themselves experience them — what they believe is happening in their bodies, and whether those experiences translate into a willingness to continue treatment. This study set out to close that gap, with the usual ethical scaffolding in place: Declaration of Helsinki compliance, institutional review board approval, trial registration (KCT0007227), and written informed consent from all participants.

Method: Listening Until Saturation

The design was deliberately qualitative. Eleven patients were purposively recruited — chosen for their experience with traditional medicine, not randomly sampled. The researchers conducted semi-structured, in-depth interviews, continuing until no new codes emerged from the transcripts. That stopping rule has a name: saturation, the point at which the thematic landscape is considered fully mapped.

Every interview was audio-recorded and transcribed verbatim, then analyzed using qualitative content analysis — a systematic method in which two researchers independently performed open coding, compared and refined their codes against the raw transcripts, and negotiated categories through consensus. Dual independent coding matters: it means no single researcher's interpretation could quietly dominate.

The analytical architecture is chronological, mirroring the patient's own journey through four categories: prior experiences with traditional medicine for other conditions; the reasons for attempting it for COPD; the experiences of treatment itself; and the shifts in attitude that followed.

Finding 1: Not One Treatment, but Three Different Experiences

The study's most striking result is that patients did not experience East Asian traditional medicine as a single, homogeneous category. Each modality produced a distinct signature.

Herbal medicine users described gradual respiratory and functional changes — slow shifts in breathing ease, sputum, and day-to-day stamina unfolding over weeks of consuming individually tailored decoctions. The studied herbal intervention, Cheongsangboha-tang (清上補下湯 in Chinese characters, Qingshang Buxia Tang in Mandarin), is a standardized decoction familiar to Chinese-medicine readers as well.

Chuna (tuina) manual therapy users emphasized immediate bodily sensations: a feeling of the chest opening, muscular relaxation, or easier sputum clearance right after a session. Acupuncture accounts were limited and varied, defying simple summary.

This temporal contrast is scientifically interesting, because it suggests the two modalities may engage different physiological pathways — one building through sustained systemic exposure to herbal compounds, the other through acute mechanical and neuromuscular effects of thoracic manipulation. It also carries a practical implication for trial design: when you measure may matter as much as what you measure. An outcome assessed too early could miss an herbal effect that builds over weeks; one assessed too late could miss a manual-therapy effect that fades quickly.

Finding 2: The Honesty About Null and Negative Experiences

The study is equally candid about experiences that did not fit a success story. Some participants described no meaningful improvement in their major respiratory symptoms at all. Favorable, unfavorable, and uncertain experiences coexisted within the same small cohort, and the researchers resist the temptation to average them into a single verdict.

That restraint is a methodological strength. Qualitative work is not designed to estimate effect sizes; it is designed to surface the full range of patient-reported phenomena, including those that trial questionnaires never capture. A patient's report that their chest felt looser after manipulation is a real datum about lived experience — even if it does not correspond to a measurable change in lung function.

Finding 3: When the Story and the Numbers Diverge

Here the study did something unusual for qualitative research. After completing the interviews, the team exploratorily compared participant-level quantitative data from previous chuna and herbal-medicine clinical studies with the symptom and functional changes the same patients described in their interviews.

Three patterns emerged. Some narratives aligned with improvements on standardized instruments — same-direction patterns. Others diverged — the story and the numbers pointed different ways. And some experiences described in the interviews had no comparable quantitative measure at all.

That third pattern is the study's quiet methodological punchline: the outcome domains used in traditional-medicine trials — forced expiratory volume in one second (FEV1), six-minute walking distance, St. George's Respiratory Questionnaire scores, dyspnea scales — may simply not be tuned to the changes patients actually notice and care about. If the instrument is deaf to the phenomenon, the phenomenon will not appear in the data. Future trials may need outcome domains that better reflect patient-described experiences.

Finding 4: What Really Decides Future Use

Perhaps the most human finding concerns what happened after treatment. Patients' attitudes toward future use were shaped less by whether a treatment had "worked" than by a cluster of practical and epistemic concerns: cost, the burden of repeated clinic visits, limited understanding of how the treatments were supposed to work, safety concerns, and the quality of communication with their physicians.

A favorable sensation that faded quickly, or an unexplained mechanism, could undermine willingness to continue even a treatment that had felt helpful. For clinicians and integrative services, the implication is direct: informed, sustained decisions require addressing expectations, explaining what is known and unknown about mechanisms, and keeping the conversation open — not dismissing the question.

How to Read a Study Like This

Studies like this one reward a particular kind of reading — the same kind we have applied in our earlier look at herbal evidence for dry eye. Three reading rules help:

1. Respect the study's own limits. Eleven patients, recruited in a Korean-medicine setting, cannot tell us whether these treatments work in general. The authors say so themselves: the findings are context-specific and should inform future research with more diverse samples. Qualitative studies generate hypotheses; they do not test them.

2. Don't confuse experience with evidence of efficacy. The coexistence of favorable, unfavorable, and uncertain experiences within one cohort is a reminder that anecdotes — however vivid — are not evidence. The study does not claim that herbal medicine, chuna, or acupuncture treats COPD. It claims something more modest and more useful: that patients experience these modalities in modality-specific, meaning-laden ways, and that any responsible research program must start from that reality.

3. Look for the design lesson. The immediate-versus-gradual contrast could directly shape the timing of outcome assessments in future trials. The story-versus-numbers mismatch could prompt trialists to add patient-derived outcome domains. This is qualitative research doing its proper job: not competing with randomized trials, but making them better.

The Bottom Line

What did eleven COPD patients feel about herbal medicine, tuina, and acupuncture? Something gradual, something immediate, something uncertain — and, in some cases, nothing at all. What matters for the rest of us is what the researchers did with those answers: they treated experience as data worth collecting rigorously, and they used it to ask whether the instruments of evidence-based medicine are measuring the right things. In a field prone to hype on one side and dismissal on the other, that is a model of scientific restraint worth studying.

If you are curious about the classical framework behind these modalities — the foundational text that shaped how Chinese medicine thinks about the body, disease, and healing — our book Huangdi Neijing: A Modern Introduction is a beginner-friendly guide.

This article is for educational purposes only and is not medical advice. It reports on a published study and its limitations; it does not recommend for or against any treatment.

References

  • Park D., Leem J., Lee B.-J., et al. Patients' experiences with East Asian traditional medicine for chronic obstructive pulmonary disease: a qualitative study focusing on herbal medicine, chuna (or tuina) manual therapy, and acupuncture. BMC Complementary Medicine and Therapies (2026). https://doi.org/10.1186/s12906-026-05618-6